Sentences with phrase «cell in the tumor»

They applied epigenetic drugs and found that the numbers of T cells in the tumor increased.

For example, because individual cells in the tumor probably carry unique mutations, they would be virtually impossible to observe with standard sequencing methods.

The researchers also conducted immune profiling before treatment for the presence of important immune system cells in the tumors.

There may be areas of dead cells in the tumor.

One found that people who had more T cells in their tumors before the treatment began tended to fare better.

We already know that if you have a lot of T cells in a tumor, you have better outcomes.

Recent findings suggest that tumor associated stroma is another important regulator of tumor growth and progression which may also modulate the recruitment, activation status and retention of immune cells in the tumor microenvironment.

Promising results of an early small trial at Duke University Medical Center in Durham, NC have suggested a new injectable agent that makes cancer cells in a tumor fluoresce, could help surgeons remove all of the cancerous tissue on the first attempt.

It is therefore important to identify cancer stem cells in tumors and characterize the differences between the different tumor cells as the basis for detecting weak spots in the course of the development of the disease,» explained Prof. Eran Meshorer, head of the Laboratory for stem cells and epigenetics in the Institute of Life Sciences and a member of the Edmond and Lily Safra Center for Brain Sciences (ELSC) of The Hebrew University of Jerusalem.

That paradox raised questions about the role of insulin signaling among other cells in the tumor microenvironment that surrounds the cancer cells, says Rask - Madsen.

«This effort moves the community beyond the barriers of most previous molecular studies that focused exclusively on immune cells in the tumor microenvironment, providing a broader picture of how our bodies and immune system respond to the challenges of the presence of a particular tumor,» Dumeaux says.

However, clinical and new experimental data indicate early tumor dissemination immediately after an angiogenic switch has occurred and an intravasation of tumor cells in the tumor core region.

Basic science is also critical: Unraveling the complex interplay of cells in the tumor microenvironment, understanding how tumor mutational load influences therapeutic efficacy, and dissecting how our resident microbes shape the development and treatment of cancer will also provide important insights that will forge the way toward improving existing therapies and developing new ones.

The team is also studying changes in the tumor microenvironment — the cells that support cancerous cells in a tumor — to see if there are changes and the environment is more or less «inhabitable» following treatment.

Our second product candidate, SNDX - 6352, is a monoclonal antibody that blocks the CSF - 1 receptor and may also block the function of immune suppressive cells in the tumor microenvironment.

An important question in the field of chemotherapy is whether resistance mutations pre-exist in rare cells in the tumor, or if they emerge spontaneously in response to therapy.

When looking for culprits, researchers have often focused their microscopes on macrophages, which occupy a meaningful spot among the white blood cells in the tumor microenvironment.

Encapsulated toxin - producing stem cells (in blue) help kill brain tumor cells in the tumor resection cavity (in green).

They showed that in typical cancers growing in mice, the invasive cells are more numerous and have a survival advantage over non-invasive cells in a tumor.

Dying cells in a tumor (upper left) or damaged tissue release DNA fragments that course through blood and that contain markers that point to their origin in the body.

«Our results suggest that sialidase could sensitize myeloid cells in tumors to previously ineffective STAT3 inhibitors,» said Vinit Kumar, Ph.D., staff scientist in the Gabrilovich laboratory at The Wistar Institute and first author of the study.

The discovery sheds light on the tiny «environments» that stem cells occupy in animal bodies and may help explain how stem cells in tumors replenish themselves, the researchers report in the May 8 issue of the journal Cell Reports.

Her current research interests are studying natural killer cells in tumor micro-environment and studying sex - based differences in immune cell subsets.

These models are used for both basic and translational research, including studies to investigate the role of tumor initiating cells in tumor relapse, tumor metastasis and therapy resistance.

Identifying cancer stem cells, the small number of cells in a tumor believed to fuel its growth and spread

In his position, Dr. Beliveau oversees a number of important angiogenesis - based research projects involving the regulation of VEGF - dependent signaling pathways, contribution of bone marrow - derived cells in tumor angiogenesis, and the identification of new molecular targets and biomarkers, among others.

Due to either or both tumor heterogeneity and / or normal contamination (presence of DNA from normal cells in the tumor sample), coverage levels may not correspond to integer - valued ploidy.

«We are excited to be a part of this important new initiative to develop novel treatment options for patients,» said Ovid Trifan, M.D., Ph.D., chief medical officer of Apexigen, Inc. «APX005M is a potential best - in - class CD40 agonist that works by activating the immune system's antigen - presenting cells in the tumor microenvironment.

Identifying and exploiting a novel mechanism that may disrupt this process by inhibiting the interactions between tumor cells and cells in the tumor environment will speed clinical investigations, and ultimately lead to improved outcomes for dogs with this devastating disease.

This Dream Team has been investigating combinations of treatments, focused on different and unique pathways involved in immune response to treatment found in the tumor and the «stroma» or the supportive environment that sustains cancer cells in tumors.

In order to identify the cancer stem cells from other cells in the tumor, the research team studied epigenetic mechanisms that distinguish between the least - sorted cells, with endless division properties and a potential to create growth, and the more sorted cells which lack this ability.

«Our test should make it possible to find drug combinations that kill ALL the cancerous cells in a tumor,» Skala said.

«We expect that the proposed treatment will be especially effective in advanced stages of ovarian cancers, where there are many cancer stem cells in the tumors that resist conventional drug treatment,» says Minko.

Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment.

Dr. Sadelain's work has focused on developing novel strategies to extend survival of CAR T cells in the body and enable T cells with increased potency to overcome the resistance imposed by tumor and other cells in the tumor microenvironment.

The latter «really just had quiescent T - cells in their tumors,» says Wargo.

In the last few years, a bulk of data pointing to a small population of cells in tumors that maintain tumor growth, are particularly resistant to chemotherapy, are responsible for relapses, and develop metastases.

Cancer progression is extremely complex, and the variation in pathogenesis along with the heterogeneity of cancer cells in tumors and metastasized cancers, makes effectively treating cancer akin to hitting a moving target.

Metastatic ovarian cancer patients treated with chemotherapy prior to surgery had altered immune cells in their tumors, and specific alterations identified suggest that immunotherapy given after chemotherapy may help in preventing the cancer from coming back, reports Frances R. Balkwill, PhD, professor of cancer biology at Barts Cancer Institute in Queen Mary University of London, United Kingdom.

According to Semenza, «Chemotherapy may kill more than 99 percent of the cancer cells in a tumor but fail to kill a small population of cancer stem cells that are responsible for subsequent cancer relapse and metastasis.»

It ultimately just doesn't matter if a given therapy kills 99 percent of the cells in a tumor.

In a second paper, also published online today in Nature, developmental biologist Luis Parada and his colleagues at the University of Texas Southwestern Medical Center (UTSMC) in Dallas show that in mice that develop glioma, a form of brain cancer, tumor growth seems to come from a small subset of cells in the tumor.

According to Herlyn, these slow - growing JARID1B cells represent only one to five percent of the cells in a tumor, yet readily divide into the fast - growing cells that are the hallmark of advanced melanoma.

The Johns Hopkins team tested ImmunoMap's ability to correlate immune responses on receptor sequencing data from T - cells in the tumors of 34 patients with cancer enrolled in a nationwide clinical trial of the immunotherapy drug nivolumab.